Genocea Biosciences is a biotechnology & medical research business based in the US. Genocea Biosciences shares (GNCA) are listed on the NASDAQ and all prices are listed in US Dollars. Genocea Biosciences employs 74 staff and has a trailing 12-month revenue of around $1.9 million.
Our top picks for where to buy Genocea Biosciences stock
How to buy Genocea Biosciences stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – GNCA. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Genocea Biosciences stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Genocea Biosciences stock price (NASDAQ: GNCA)
Use our graph to track the performance of GNCA stocks over time.Genocea Biosciences shares at a glance
Latest market close | $0.00 |
---|---|
52-week range | $0.00 - $0.00 |
50-day moving average | $0.00 |
200-day moving average | $0.11 |
Wall St. target price | $3.08 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-0.53 |
Is it a good time to buy Genocea Biosciences stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Genocea Biosciences price performance over time
Historical closes compared with the close of $0.0002 from 2023-02-24
1 week (2024-08-24) | N/A |
---|---|
1 month (2024-07-31) | N/A |
3 months (2024-05-31) | N/A |
6 months (2024-02-29) | N/A |
1 year (2023-08-31) | N/A |
---|---|
2 years (2022-09-02) | -98.02% |
3 years (2021-09-03) | 1.82 |
5 years (2019-09-04) | 3.44 |
Genocea Biosciences financials
Revenue TTM | $1.9 million |
---|---|
Gross profit TTM | $1.6 million |
Return on assets TTM | -57.59% |
Return on equity TTM | -525.78% |
Profit margin | 0% |
Book value | $0.21 |
Market Capitalization | $5,878 |
TTM: trailing 12 months
Genocea Biosciences share dividends
We're not expecting Genocea Biosciences to pay a dividend over the next 12 months.
Have Genocea Biosciences's shares ever split?
Genocea Biosciences's shares were split on a 1:8 basis on 21 May 2019. So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Genocea Biosciences shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Genocea Biosciences shares which in turn could have impacted Genocea Biosciences's share price.
Genocea Biosciences share price volatility
Over the last 12 months, Genocea Biosciences's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Genocea Biosciences's is 1.6038. This would suggest that Genocea Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Genocea Biosciences overview
Genocea Biosciences, Inc. , a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.
Frequently asked questions
nullWhat percentage of Genocea Biosciences is owned by insiders or institutions?
Currently 6.222% of Genocea Biosciences shares are held by insiders and 1.249% by institutions. How many people work for Genocea Biosciences?
Latest data suggests 74 work at Genocea Biosciences. When does the fiscal year end for Genocea Biosciences?
Genocea Biosciences's fiscal year ends in December. Where is Genocea Biosciences based?
Genocea Biosciences's address is: 100 Acorn Park Drive, Cambridge, MA, United States, 02140 What is Genocea Biosciences's ISIN number?
Genocea Biosciences's international securities identification number is: US3724274010 What is Genocea Biosciences's CUSIP number?
Genocea Biosciences's Committee on Uniform Securities Identification Procedures number is: 372427401
More guides on Finder
-
Options profit calculator
Use this calculator to quickly see potential outcomes of your options trades.
-
Best options trading platforms of 2024
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
-
What is a covered call?
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
-
GSD Capital review 2024
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
10 E*TRADE competitors worth your time
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
-
Charles Schwab vs. Fidelity
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
-
Interactive Brokers review 2024: Tailored trading and investing
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
-
Top 15 tech stocks to invest in for 2024
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Ask a question